Form 4: Athira Pharma CSO Granted Stock Options

Athira Pharma's Chief Scientific Officer, Kevin Church, was granted options to purchase 35,138 shares of common stock at an exercise price of $4.07.

Summary

• Kevin Church, Chief Scientific Officer of Athira Pharma, Inc. (ATHA), was granted an option to purchase 35,138 shares of common stock.
• The exercise price for these options is $4.07 per share, which was the closing price on the Nasdaq Global Market on the grant date.
• The option grant was made on September 24, 2025, with the earliest transaction date reported as December 24, 2025.
• Vesting of the options is contingent upon satisfying both a milestone requirement and a service-based requirement.
• The milestone requirement was satisfied on December 23, 2025.
• The service-based requirement dictates that 50% of the options will vest on December 23, 2026, with the remaining 50% vesting at 1/36th per month thereafter, provided continued service.

Sentiment

Score: 6

Explanation: The filing reports a routine stock option grant to a key executive, which is a positive for aligning management incentives but does not represent a significant market-moving event or fundamental change in the company's outlook.

Positives

• The grant of stock options aligns the Chief Scientific Officer's financial interests with those of the shareholders, incentivizing long-term performance.
• The satisfaction of a milestone requirement indicates progress towards a specific company objective.

Future Outlook

The vesting schedule for the stock options extends into the future, with a significant portion vesting in December 2026 and monthly thereafter, contingent on the Chief Scientific Officer's continued service to the company.

Industry Context

The grant of stock options to a Chief Scientific Officer is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive compensation packages designed to attract, retain, and incentivize top talent.

Comparison to Industry Standards

• Equity compensation, such as stock options with performance and service-based vesting, is a standard practice for executive remuneration in the biotech sector, comparable to practices at companies like Biogen or Amgen, which frequently use such incentives to align executive and shareholder interests.
• The structure of vesting, combining a milestone requirement with a service-based component, is typical for incentivizing both performance achievement and long-term commitment, similar to plans observed at emerging growth companies in the life sciences space.

Corporate Governance

Stakeholder Impact

• Shareholders: The option grant aims to align the Chief Scientific Officer's long-term interests with shareholder value creation, potentially leading to improved performance and strategic decisions.
• Employees: The compensation structure for a key executive may influence overall compensation philosophy and morale within the company.

Next Steps

• Continued service by the Chief Scientific Officer to meet the service-based vesting requirements.
• Future vesting of 50% of the options on December 23, 2026, and subsequent monthly vesting.

Key Dates

Recommendation

This Form 4 reports a routine stock option grant to a key executive, which is a standard component of compensation and aligns management incentives with shareholder interests. It does not provide new information that would alter the fundamental investment thesis for Athira Pharma, Inc., thus a 'hold' recommendation remains appropriate based solely on this filing.

Keywords

Athira Pharma, ATHA, Stock Option, Insider Transaction, Kevin Church, Chief Scientific Officer, Equity Incentive Plan, Vesting